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A B S T R A C T
Objective: To evaluate the misdiagnosis between endometrial biopsy and deﬁnitive surgical pathology
and to assess whether the failure in recognizing preoperatively high-risk endometrial carcinoma (EC)
can impact oncological outcomes.
Study design: A retrospective study was conducted to evaluate patients with EC diagnosed by
preoperative endometrial biopsy who subsequently underwent surgical staging between 2006 and 2013
at our institution. In patients with a surgical diagnosis of high-risk EC, histotype and grade change
between the endometrial biopsy and surgical specimen (discordance diagnosis) were evaluated and
correlated to survival outcomes. Cox’s regression model for multivariable analysis was used to evaluate
the effect of several variables (age, stage, discordance in diagnosis, co-morbidities, frozen section,
extensive surgical staging and adjuvant chemotherapy) on the survival rate.
Results: Data from 447 patients were reviewed. Among 109 women with surgical diagnosis of high-risk
EC, 35 (32.1%) were preoperatively misdiagnosed. Of these 35 women, 24 (68.6%) cases were upgraded to
grade 3, and 11 (3.4%) were upgraded to serous or clear cell type in the deﬁnitive specimen. The 5-year
overall survival (OS; 70.2 vs. 86.8%; p = 0.029), disease-speciﬁc survival (DSS; 72.5 vs. 88.2%; p = 0.039)
and recurrence free survival (RFS; 62.6 vs. 82.5%; p = 0.024) were signiﬁcantly lower in the high-risk EC
patients who were preoperatively undiagnosed in the endometrial biopsy compared with patients with
an appropriate preoperative histological diagnosis. Controlling for age, stage, co-morbidities, frozen
section, extensive surgical staging and adjuvant chemotherapy, multivariable analysis revealed that
discordance in diagnosis was associated with poorer survival outcomes.
Conclusion: Failure to recognize preoperatively high-risk ECs is associated with worse outcomes.
 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Endometrial carcinoma (EC), the most frequent gynecological
tumor, represents a complex and heterogeneous disease consisting
of different grades and various histotypes [1,2].
Non-endometrioid histotypes [serous (SEC) and clear cell
(CCEC)] and high-grade endometrioid EC (G3 EEC) are typically
more clinically and biologically aggressive and represent the
leading cause of EC-related mortality [3,4].* Corresponding author at: Unit of Obstetrics and Gynaecology, ‘‘Tommaso
Campanella’’ Cancer Center of Germaneto, Department of Experimental and Clinical
Medicine, ‘Magna Graecia’ University, Viale Europa, Loc. Germaneto, 88100
Catanzaro, Italy. Tel.: +39 3386249331; fax: +39 0961883234.
E-mail address: annalisa_dicello84@yahoo.it (A. Di Cello).
http://dx.doi.org/10.1016/j.ejogrb.2015.09.004
0301-2115/ 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access 
nd/4.0/).Surgical staging has a crucial role in the management of affected
patients. Grading, histology, myometrial inﬁltration (MI), tumor
size, lymph nodes status are the criteria used to guide the
treatment [5–9]. Information about grade and histology are
derived in most cases from endometrial biopsies performed before
surgery. However, grade and histology changes between the
preoperative biopsy and the surgical specimen have been observed
[10]. When this happens, a surgical decision based on the
preoperative diagnosis could be inappropriate.
Furthermore, over the last 2 years, some groups [11–15] have
investigated the prognostic value of different molecular alterations
involved in endometrial carcinogenesis. They have demonstrated
that the genomic features of ECs allow for reclassiﬁcation, which
may help in choosing the surgical and adjuvant treatment for
women with aggressive tumors.article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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20] characterization will probably become the best approaches for
the identiﬁcation of aggressive forms of ECs regardless of the
microscopic criteria.
However, for now, none of the new molecular biomarkers have
been incorporated into routine clinical practice.
To guide the surgical management of EC patients more
effectively, some centers use frozen sections (FS) to obtain further
information intraoperatively about the tumor grade, histotype and
MI [21–24]. Nevertheless, it was observed that the intraoperative
assessment of the histological grade has lower sensitivity and that
the quality of FS can be very institution dependent [25,26]. Fur-
thermore, in a recent survey [27], it has been shown that at least
two-thirds of gynecologic surgeons do not use FS in their decision
making for EC management.
In our unit, we use always FS of the uterus to evaluate MI in
cases in which the preoperative MI is inconclusive in order to
decide whether a pelvic lymphadenectomy should be performed
on pelvic lymph nodes, and if they are removed, to guide the
decision about para-aortic lymphadenectomy. Regarding the grade
and histotype, our decisions are based on the histological
preoperative analysis [28].
We have recently observed that among our patients with high-
risk EC, a great number of the deﬁnitive histological diagnoses do
not correspond to the preoperative diagnoses, and thus we decided
to retrospectively review the data from our center.
Materials and methods
Objective
The objective of this study was to evaluate the discordance in
grade and histology between endometrial biopsy and deﬁnitive
surgical pathology and to assess whether failure to recognize
preoperatively high-risk EC modiﬁed the oncological outcomes at
our institution.
Patients and study design
The procedures used in this retrospective cohort study were in
accordance with the guidelines of the Helsinki Declaration on
Human Experimentation and Good Clinical Practice (CGP). Despite
the retrospective manner of the study, approval by the Institu-
tional Review Board was obtained. Furthermore, written consent
was obtained from all patients before processing their data from
the time of the hospitalization, even if the data did not include any
personal identifying information.
The inclusion criteria included all women with a preoperative
diagnosis on the endometrial biopsy of EC who subsequently
underwent surgical staging between October 2006 and November
2013. Data from 447 consecutive patients treated for EC at the
Unit of Gynaecologic Oncology, Magna Graecia University,
Germaneto, and Pugliese-Ciaccio Hospital, Catanzaro, Italy, were
collected from the charts. The exclusion criteria were having a
previous or concurrent cancer located in other sites, genetic
susceptibility to gynecologic or non-gynecologic cancer, neoad-
juvant chemotherapy or hormonal treatment before the hyster-
ectomy, the absence of a preoperative biopsy demonstrating
endometrial cancer.
Changes in the grade and histotype between the endometrial
biopsy and the surgical hysterectomy specimen were evaluated in
all patients. Only patients with a surgical diagnosis of high-risk EC
were included in the survival analysis. We deﬁned ‘‘high-risk’’ as
EEC G3, SEC and CCEC and ‘‘low-risk’’ as EEC G1-G2 [29]. According
to the change in grade and histotype in the surgical specimens
compared with the preoperative biopsy, high-risk EC patients weresub-grouped into two groups: ‘‘concordant diagnosis’’ and
‘‘discordant diagnosis’’. We deﬁned ‘‘discordant’’ as all cases in
which a cancer was preoperatively down-graded (e.g., an EEC G3
misdiagnosed as a G1 or G2), or when a rare histological type (SEC
or CCEC) was incorrectly diagnosed as an EEC. Those cases of SEC
and CCEC that were misdiagnosed as EEC G3 were included in the
discordant group. Indeed, even if in these cases the misdiagnoses
does not impact classiﬁcation as ‘‘high-risk’’; however, the
misdiagnoses affect the surgical treatment decision (SEC and
CCEC always require extensive surgery while the extent of surgery
for patients with EEC G3 depends on MI) [21]. The clinical,
pathological and surgical data from the concordant and discordant
groups of high-risk patients were compared.
Among eligible cases, the following information was abstracted
from the medical records: clinical features including age, ASA
score, and major medical co-morbidities including obesity,
hypertension, diabetes mellitus, and bleeding disorders; tumor
characteristics including the tumor grade and histology from the
endometrial biopsy as well as hysterectomy specimens and the
International Federation of Gynaecology and Obstetrics (FIGO)
stage; treatment characteristics including the extent of the
surgery, whether any lymph nodes were removed, FS execution
and adjuvant treatment use; survival data including overall
survival (OS), disease-free survival (DFS), recurrent free survival
(RFS) and the mortality rate (MR). Surgical treatment was deﬁned
as ‘‘standard surgery’’ when hysterectomy, bilateral salpingo-
oophorectomy (BSO) and peritoneal cytology with or without
pelvic lymphadenectomy were performed; the term ‘‘extensive
surgery’’ identiﬁes a surgical approach in which peritoneal
cytology, hysterectomy, BSO, omentectomy, peritoneal biopsies,
pelvic and para-aortic lymphadenectomy were performed.
According to the international guidelines [28], our decision
making model for the treatment of EC patients at our institution is
described in the Fig. 1.
Statistical methods
The Chi square test was used to compare categorical variables,
while the t-test was used to compare continuous variables.
The oncological outcomes, the 5-year OS, DSS, and RFS, were
evaluated using a Kaplan–Meier curves analysis to examine the
differences in survival between patients with discordant and
concordant diagnoses. p-Values were obtained using the log-rank
test.
MR was evaluated as the ratio between the number of deaths
and the total number of high-risk patients included in the study.
The survival effect of several factors (patient age, major co-
morbidities, FIGO stage, discordance in diagnosis, extensive
surgical staging, adjuvant chemotherapy and FS) was evaluated
by Cox’s proportional hazard regression model for multivariate
analysis.
Survival analysis expressed the magnitude of statistical
signiﬁcance by the hazard ratio (HR) and 95% CI. In the
multivariable model, each of the following covariates were
selected a priori for inclusion in any ﬁnal model based on clinical
relevance and effect in EC: age (< or 62 years), FIGO stage (I–II or
III–IV), major co-morbidities (present or absent), failure to
recognize a high-risk tumor preoperatively (discordant vs.
concordant diagnosis), surgical under-staging (present or absent),
adjuvant chemotherapy (performed or not), and FS execution
(performed or not).
Variables were regarded as signiﬁcant at the p < 0.05 level.
Correlation Matrix of Regression Coefﬁcients were examined to
assess the multi-collinearity of variables included in the ﬁnal
model. Analyses were conducted using SPSS version 20 (SPSS,
Chicago, IL).
Fig. 1. Algorithm for surgical management of endometrial cancer at our institution before and after the second half of 2010. Before 2010 (A), in the presence of an EEC G3, para-
aortic lymphadenectomy was performed only if there was a positivity of the pelvic nodes at the intraoperative FS assessment. From the second half of 2010 (B), peritoneal
cytology, hysterectomy and bilateral salpingo-oophorectomy (BSO) is the treatment of choice for patients with a preoperative diagnosis of endometrioid histotype G1–G2 and
with a myometrial inﬁltration (MI) < 50% (MI is routinely preoperatively evaluated by imaging), without other risk factors for lymph nodes involvement (age, unsuspecting
imaging data, a primary tumor size <2 cm, and no cervical involvement); peritoneal cytology, hysterectomy and BSO with pelvic lymphadenectomy are performed for cases of
endometrioid histotype G1–G2 with MI > 50%, or for cases with a high grade endometrioid sub-type (G3); para-aortic lymphadenectomy, omentectomy and peritoneal
biopsies are performed only in patients with nonendometrioid histotypes or in patients with high grade endometrioid sub-type, and when the pelvic nodes are positive by
frozen section (FS).
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A total of 447 patients with EC underwent a hysterectomy
during the study period. Among these, 338 patients had a surgical
diagnosis of low-risk (EEC G1–G2) and 109 had a surgical
diagnosis of high-risk EC (80 cases of EEC G3, 15 cases of SEC
and 14 of CCEC).
In a comparison of the preoperative diagnosis with that
obtained from the surgical hysterectomy specimen, a change ingrade and histotype was observed in 61 (18.0%) of the 338 low-risk
EC patients and 35 (32.1%) of the 109 high-risk EC patients. Among
the reviewed patients with a surgical diagnosis of low-risk EC,
61 cases were upgraded from G1 to G2 upon examination of the
surgical specimens. Out of the 109 patients with a surgical
diagnosis of high-risk EC, 35 were misdiagnosed preoperatively.
We found 24 (68.6%) women whose tumors were upgraded to G3
and 11 (3.4%) women whose tumors were upgraded to serous or
clear cell types in the deﬁnitive surgical diagnosis.
Table 1
Histological features of high-risk EC patients grouped by pre- and post-operative
histology.
Pre-operative
histology (n)
Post-operative histology (n, %)
G3 EEC (80) SEC (15) CCEC (14)
EEC G1 (7) 5 (6.0) 1 (6.7) 1 (7.2)
EEC G2 (24) 19 (24.0) 2 (13.3) 3 (21.4)
EEC G3 (60) 56 (70.0) 2 (13.3) 2 (14.3)
SEC (10) 0 10 (66.7) 0
CCEC (8) 0 0 8 (57.1)
Data are expressed as number and percentage. EEC: endometrioid endometrial
cancer; G1, 2, 3: grading 1, 2 and 3; SEC: serous endometrial cancer; CCEC: clear cell
endometrial cancer.
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affected by high-risk ECs at the time of surgical diagnosis.
The pre- and postoperative histological characteristics of the
patients with deﬁnitive high-risk diagnoses are shown in Table 1.
The clinical, pathological and surgical data of high-risk EC
patients are shown in Table 2. No signiﬁcant difference in the mean
age, major medical co-morbidities, FIGO stage prevalence were
observed between the patients with discordant and concordant
diagnoses (Table 2).
No signiﬁcant difference was observed in the percentage of
patients who underwent FS intraoperatively between the two
groups (71.4% of the discordant group and 54.1% of the concordant
one, p = 0.07) (Table 2).
The rate of high-risk patients who underwent extensive surgery
was signiﬁcantly lower in the ‘‘discordant’’ group than the
‘‘concordant’’ group (37.1 vs. 59.5%; p = 0.029).Table 2
Clinical, pathological and surgical characteristics of patients with high-risk
endometrial cancer.
Discordant
diagnosis (35)
Concordant
diagnosis (74)
p-Value
Age (years) 62.5  12.0 63.1  10.7 0.832
BMI (kg/m2) 33.4  5.4 34.2  6.0 0.321
FIGO stage (n, %)
Stage I 14 (40.0) 33 (44.6) 0.651
Stage II 9 (25.7) 16 (21.6) 0.635
Stage III 11 (31.4) 25 (33.8) 0.958
Stage IV 1 (2.8) 1 (1.35) 0.828
Tumor type (n, %)
EEC G3 24 (30.0) 56 (70.0) 0.433
SEC 5 (33.3) 10 (66.7) 0.002
CCEC 6 (43.0) 8 (57.0) 0.356
ASA score (n, %)
1 22 (62.9) 47 (63.5) 0.947
2 10 (28.6) 21 (28.4) 0.983
>2 3 (8.6) 6 (8.1) 0.935
Extensive surgery (n, %) 13 (37.1) 44 (59.5) 0.029
Pelvic nodes removed 15.0  5.0 17.0  7.0 0.132
Para-aortic nodes removed 12.0  4.0 14.0  6.0 0.070
Frozen section (n, %) 25.0 (71.4) 40.0 (54.1) 0.120
Lymph node metastasis
Positive 4 18 0.883
Negative 9 56
LVSI (n, %) 6/13 (38.4) 11/28 (39.3) 0.749
Chemotherapy (n, %) 19 (54.3) 49 (66.2) 0.229
Radiotherapy (n, %) 12 (34.29) 25 (33.78) 0.869
Major comorbidities (n, %) 14 (40.0) 31 (41.9) 0.851
Data are expressed as mean  SD, number and percentage. BMI: body mass index;
FIGO: International Federation of Gynecology and Obstetrics. ASA: American Society of
Anesthesiologists; extensive surgery: peritoneal cytology, hysterectomy, bilateral
salpingo-oophorectomy (BSO), omentectomy, peritoneal biopsies, with pelvic and
para-aortic lymphadenectomy were performed; LVSI: lymphovascular space invasion.
LVSI was not always described in the pathologic response. It was available for 13 and
28 patients in the discordant and concordant diagnosis group respectively.In the concordant group, extensive surgical staging was not
performed in almost 40% of patients who had EEC G3 and a
MI < 50% and underwent pelvic but not para-aortic lymphadenec-
tomy due to the negativity of the pelvic nodes at the intraoperative
FS assessment. In the ‘‘discordant’’ group, the extensive surgery
was not performed in a total of 22 patients. Of these, 15 patients
were upgraded to EEC G3 and 7 to rare histological types (3 SEC and
4 CCEC) from the hysterectomy surgical specimen. The 15 EEC G3
patients did not undergo extensive surgical staging because in 8
cases (5 G1 and 3 G2) there was a MI < 50%, and in 7 cases (all
preoperatively misdiagnosed as G2) with a MI > 50% there were
negative pelvic nodes at FS.
The 7 discordant patients with rare histotypes did not undergo
extensive surgery because in one case (down-graded preopera-
tively in EEC G1) the MI < 50% and in 6 patients (down-graded
preoperatively in EEC G1 and G2) the MI > 50% but the pelvic
nodes were negative at FS.
No signiﬁcant difference in the mean number of pelvic
(15  5 vs. 17  7; p = 0.132) and para-aortic (12  4 vs. 14  6;
p = 0.076) lymph nodes removed was found between the two groups.
No signiﬁcant difference in terms of the percentage of patients who
underwent chemotherapy and radiotherapy was observed between
the ‘‘discordant’’ and ‘‘concordant’’ groups (54.3 vs. 66.2%; p = 0.229).
From our analysis, a great portion (73%) of preoperative diagnosis
were performed on endometrial biopsies collected by hysteroscopy.
The remaining 27% of cases received a preoperative diagnosis on
endometrial curettage.
The 5-year OS (70.2 vs. 86.8%; p = 0.029), DSS (72.5 vs. 88.2%;
p = 0.039) and RFS (62.6 vs. 82.5%; p = 0.024) estimated by the
Kaplan–Meier method were signiﬁcantly lower in the ‘‘discordant’’
group compared with the ‘‘concordant’’ group (Fig. 2A–C; Table 3).
A signiﬁcantly higher MR (54.29 vs. 28.38%, p = 0.016), and
lower months/years of follow up (41.71  22.64 vs. 51.19  17.83,
p = 0.019) were observed in the discordant group than in the
concordant group. Overall, 17.39% of deaths were not cancer-related.
Recurrence rate at 3 years was 8.11 and 28.57 in concordant and
discordant group respectively (p = 0.011).
A total of 9 patients were lost during the follow up period but
they have been included in the survival analysis until their
withdrawal.
When discordant preoperative diagnoses were examined using
Cox’s proportional hazard regression test controlling for other
covariates, failure to recognize high-risk EC preoperatively
negatively impacts OS (HR 3.356, 95% CI 1.280–8.801;
p = 0.014). Advanced-stage disease (HR 2.088, 95% CI 1.106–
3.945; p = 0.023) at the time of hysterectomy were associated with
decreased OS by multivariable analysis; Age less than 62 years (HR
0.948, 95% CI 0.918–0.995; p = 0.011), and extensive surgical
staging (HR 0.319, 95% CI 0.118–0.867; p = 0.018) signiﬁcantly
improved the OS (Table 4). FS execution (p = 0.207), the presence of
major medical co-morbidities (p = 0.212) and chemotherapy
administration (p = 0.083) did not signiﬁcantly impact the OS.
No collinearity was observed between all variables included in
the ﬁnal model (SPSS version 20, Chicago, IL).
Discussion
This retrospective study found that failure to recognize
preoperatively high-risk ECs is an important issue accounting
for 32.1% of grade and histotype change between the deﬁnitive
surgical pathology and the preoperative biopsy. Moreover, we
observed that changes from a low-risk tumor in the endometrial
biopsy to a high-risk tumor in the deﬁnite pathology were
associated with worse survival outcomes.
Our retrospective study, indirectly conﬁrms the very recent
understanding that better molecular characterization of ECs is
Fig. 2. Kaplan–Meier analysis of overall (A), disease-speciﬁc (B), and recurrence-free (C) survival for patients with high-risk endometrial cancer according to accuracy of
preoperative diagnosis.
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or medical treatment [15].
In our setting, two-thirds of cases that were preoperatively
misdiagnosed (68.6%) were upgraded to EEC G3 by deﬁnitive
pathology. This observation conﬁrms the results of several prior
studies [1,16,18,20,30] that demonstrated that EEC G3 often
exhibits confounding morphologic features that may result in a
misdiagnosis of both grade and histotype.
The EEC G3 has clinical, histopathological and molecular features
that are intermediate between those of low- and high-risk types.Table 3
Oncologic outcomes in high-risk EC patients with ‘‘discordant’’ and ‘‘concordant’’
preoperative diagnosis.
Discordant
diagnosis (35)
Concordant
diagnosis (74)
p-Value
Overall survival (%) 70.20 86.80 0.029
Disease speciﬁc survival (%) 72.50 88.20 0.039
Recurrence-free survival (%) 62.60 82.50 0.024
Data are expressed as percentage of survival or patients number.However, a large proportion is more similar to aggressive none-
ndometrioid carcinoma than to endometrioid carcinoma [2,31,32]
and should be subjected to surgical and chemotherapy treatments
suitable for these aggressive ECs.
Our results are in agreement with data of a signiﬁcant larger,
prospective multicenter study authors observed that discordant
preoperative diagnosis represents a risk factor for metastasis and
bad prognosis [33].
More recently, a retrospective analysis [10] reported a
signiﬁcant frequency of grade change from low- to high-grade
and indirectly conﬁrmed our observation about the survival
impact of a deﬁnitive upgrading. In this paper, Matsuo et al. [10]
suggested that the cause of this change in diagnosis between the
endometrial biopsy and the surgical hysterectomy is mainly due to
a sampling bias at the time of endometrial biopsy in that an
underlying high-grade tumor is missed at the time of biopsy
[17,18].
We are in agreement with the observation that the failure to
recognize preoperatively high-risk EC carcinoma is often related
to an excessive number of preoperative diagnoses made on
Table 4
Cox regression analysis.
Unadjusted hazard ratio (95% CI) p-Value Adjusted hazard ratio (95% CI) p-Value
Diagnosis
Concordant 1.00 1.00
Discordant 3.552 (1.282–9.837) 0.009 3.356 (1.280–8.801) 0.014
Surgical staging
Standard 1.00 1.00
Extensive 0.276 (0.088–0.998) 0.014 0.319 (0.118–0.867) 0.018
Age-group (years)
<62 0.967 (0.911–0.986) 0.007 0.948 (0.918–0.995) 0.011
62 1.00 1
FIGO stage
I–II 1.00 1.00
III–IV 3.126 (1.348–4.132) 0.018 2.088 (1.106–3.945) 0.023
Cox regression analysis of signiﬁcant prognostic factors in overall survival for patients with high-risk endometrial cancer surgically treated. Adjuvant Chemotherapy
(p = 0.083), frozen section (p = 0.207) and Medical Comorbidities (p = 0.212) were not included in the ﬁnal equation because they have not reached the statistical signiﬁcativity.
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that the preoperative availability of a greater amount of
endometrium, such as that obtained by a curettage, could reduce
the change in grade and histotype between preoperative and
deﬁnitive diagnoses.
On the contrary, the bias cannot totally correct for EEC G3, for
which the diagnostic difﬁculty is mainly related to the intrinsic
biological tissue variability of the disease [1,34].
Our most critical ﬁnding is that the preoperative misdiagnosis
of high-risk ECs might result in worse prognosis, probably due to
sub-optimal surgical staging. Our analysis has shown that patients
with a deﬁnitive diagnosis of high-risk EC, which were correctly
identiﬁed at the preoperative evaluation, had a statistically
signiﬁcant advantage in OS, DSS and RFS compared with patients
with a discordant preoperative diagnosis.
The Cox regression model conﬁrmed that, beside well-known
risk factors such as age and stage, the diagnostic discordance
alone predicts worse survival. Why would the failure to
preoperatively recognize high-risk EC worsen the prognosis?
Our analysis showed that the rate of patients who underwent
extensive surgical staging was signiﬁcantly reduced in EC
patients whose tumors were underestimated preoperatively. As
a matter of fact, the survival analysis by Cox regression showed
that extensive surgical staging improves survival in patients with
high-risk ECs.
Because none of the patients with discordant diagnoses
underwent re-intervention to complete the staging of the disease
because there is no consensus on this matter [23], it is plausible
that the patients who received less extensive surgery were under-
staged. Although the stage distribution in the two groups studied
was comparable, it isn’t highly likely that the group of high-risk ECs
patients with a preoperative diagnosis of low-risk EC would have
been undergone a stage shift to a higher stage (Will Rogers effect) if
the extent of surgical staging had been comparable between the
two groups. That could account for the difference in the survival
outcomes between the two groups of patients.
From the survival analysis, we found that the FS execution did
not improve the prognosis, probably because the surgical under-
staging persists regardless of the FS (in the results section we
showed that 50% of under-graded high-risk EC patients were
submitted to FS, but because MI resulted in <50% or the pelvic
nodes were negatives, extensive surgery was not performed).
Therefore, our current surgical approach seems most appropri-
ate: in the presence of an EEC G3, an extensive surgical staging is
performed directly without FS on pelvic lymph nodes [35,36]. In-
deed, it has been demonstrated that, unlike patients with low-risk
ECs [37,38], up to 16% of patients with high-risk EC might have
isolated involvement of the para-aortic lymph nodes [39].Unfortunately, the wide use of FS does not correct for this
difference because the sensibility of intraoperative evaluation is
dependent on the MI and lymph node evaluation but much less
reliable in histological grade assessment. Furthermore, because
intraoperative evaluation is expensive and not available in many
centers where the pathology service may be off-site, this further
explains the limited use of FS. Based on these observations, the vast
majority of ECs are managed without the routine use of FS on
surgical specimens, and FS is reserved for inconclusive MI and for
pelvic lymph node evaluations. This limited use of FS is further
inﬂuenced by the generalized lowering of both direct and indirect
health expenses in the past year (prolonged operating room
occupancy).
Further limitation of FS use derives from the fact that, as we said
above, the poor prognosis of EEC G3 depends on the biological
variability of this speciﬁc EC subtype and that in at least 25% of
cases, the molecular proﬁle and prognostic features are compara-
ble to those of rare EC histotypes [2,11]. It is obvious that the
preoperative discrimination of the more aggressive EEC G3
subtypes could be useful to personalize surgical treatment
[40]. In the presence of high-grade EEC preoperatively undiag-
nosed, the intraoperative positivity of the pelvic lymph nodes
would suggest para-aortic lymphadenectomy but not omentect-
omy and that, instead, surgery should be performed for high-risk
EC, which has a preference for peritoneal and omental dissemi-
nation.
Whereas FS alone gives us no information on the biological
aggressiveness of the tumor, the identiﬁcation and the use of new
immunohistochemical and serum biomarkers, as well as a more
careful molecular characterization of the tumor, appears to be the
best combination of diagnostic tools to distinguish between EC
subtypes. In this regard, in addition to genomic characterization,
some panels of IHC markers (such as PTEN, b-catenin, KRAS, p16,
IMP3, p53 and WT1) have been proposed as reliable diagnostic
tools to distinguish between EC subtypes; however, the pathogno-
monic immunophenotypic proﬁle for low/moderate and high
grade have not been identiﬁed.
We recently found [41] that DJ-1, a multifunctional cancer and
Parkinson’s disease-associated protein [42], was expressed in
tissue and blood and could represent an indicator of EC grading and
histotype. Since in our experimental study, approximately 37% of
EEC G3 had an IHC pattern for this biomarker more similar to that
of SEC than EEC, it is reasonable to assume that the increased
expression of DJ-1 in these speciﬁc cases could be considered as a
marker of EEC G3 biological behavior. For this reason, we are
including IHC staining and serum dosing of DJ-1 protein at our
institution to supplement the routine examination for each of our
patients affected by EC.
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endometrioid-like tumors can be difﬁcult despite the use of
additional immunohistochemical markers and expert pathologists.
Other tools such as predictive modeling tools were developed to
identify those patients with high risk EC [43,44]. Therefore, only a
careful molecular (genomic and/or proteomic) characterization
[11,12] will allow for the preoperative differentiation of ECs with
indolent behavior from those with a particularly aggressive genetic
and clinical proﬁle.
Conclusions
Our data demonstrate that the preoperative pathological exam
is often inaccurate for the diagnosis of high-risk ECs.
Our ﬁndings represent a ‘‘warning’’ for all of those oncologic
centers that refer to the preoperative diagnosis in endometrial
biopsy for deciding the management of patients with EC. The use of
FS for pelvic lymph nodes and MI evaluation is not able to correct
this risk.
For this reason, either revise the slide or performing an
extensive endometrial curettage in inconclusive cases may correct
this bias.
This issue could be improved by integrating routine preopera-
tive histological examination with a detailed evaluation performed
at a pathological referral center, which could improve the histology
characterization and biological behaviors of the EEC G3. Probably
in the near feature a more accurate immunohistochemical and
genomic characterization will be the best strategy in terms of both
diagnostic accuracy and cost-effectiveness compared with the
extensive use of FS.
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